CellOrigin closes a new round of investment funding

By The Science Advisory Board staff writers

April 1, 2022 -- CellOrigin, a biotech company focusing on immune cell therapies derived from induced pluripotent stem cells (iPSC), has secured a new round of approximately 100 million ​​renminbi (approximately $16 million U.S.) of investment funding.

The company said it aims to make engineered clonal off-the-shelf immune cell products derived from iPSC in large scale for cancer immunotherapy applications.

Investors for this funding round included Jifeng Ventures, Kunlun Capital, Yinxinggu Capital, and Efung Capital.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.